/
/
/

Divi's Laboratories Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2015Dec 2014Mar 2014Dec 2013Mar 2013Dec 2012Mar 2012Mar 2011Dec 2010Sep 2010Jun 2010Mar 2010Dec 2009Sep 2009Jun 2009Mar 2009Dec 2008Sep 2008Jun 2008Mar 2008
₹3080 Cr₹2831 Cr₹2604 Cr₹2715 Cr₹2410 Cr₹2585 Cr₹2319 Cr₹2338 Cr₹2118 Cr₹2303 Cr₹1855 Cr₹1909 Cr₹1778 Cr₹1951 Cr₹1708 Cr₹1855 Cr₹2255 Cr₹2518 Cr₹2493 Cr₹1988 Cr₹1961 Cr₹1788 Cr₹1701 Cr₹1749 Cr₹1730 Cr₹1390 Cr₹1396 Cr₹1446 Cr₹1163 Cr₹1267 Cr₹1360 Cr₹1324 Cr₹995 Cr₹821 Cr₹797 Cr₹750 Cr₹690 Cr₹658 Cr₹531 Cr₹722 Cr₹480 Cr₹313 Cr₹259 Cr₹265 Cr₹315 Cr₹204 Cr₹227 Cr₹218 Cr₹324 Cr₹270 Cr₹333 Cr₹267 Cr₹278 Cr
₹64 Cr₹155 Cr₹88 Cr₹145 Cr₹119 Cr₹86 Cr₹82 Cr₹106 Cr₹79 Cr₹79 Cr₹95 Cr₹86 Cr₹81 Cr₹66 Cr₹113 Cr₹80 Cr₹88 Cr₹52 Cr₹17 Cr₹19 Cr₹36 Cr₹24 Cr₹19 Cr₹14 Cr₹17 Cr₹77 Cr₹42 Cr₹47 Cr₹30 Cr₹41 Cr₹34 Cr₹80 Cr₹49 Cr₹11 Cr₹24 Cr₹9 Cr₹4 Cr₹8 Cr₹18 Cr₹1 Cr₹10 Cr₹7 Cr₹6 Cr₹5 Cr₹6 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹3 Cr₹2 Cr₹2 Cr₹5 Cr
₹3144 Cr₹2986 Cr₹2692 Cr₹2860 Cr₹2529 Cr₹2671 Cr₹2401 Cr₹2444 Cr₹2197 Cr₹2382 Cr₹1950 Cr₹1995 Cr₹1859 Cr₹2017 Cr₹1821 Cr₹1935 Cr₹2343 Cr₹2571 Cr₹2510 Cr₹2007 Cr₹1997 Cr₹1812 Cr₹1721 Cr₹1763 Cr₹1748 Cr₹1466 Cr₹1438 Cr₹1493 Cr₹1193 Cr₹1308 Cr₹1394 Cr₹1404 Cr₹1044 Cr₹832 Cr₹821 Cr₹760 Cr₹694 Cr₹665 Cr₹549 Cr₹723 Cr₹490 Cr₹320 Cr₹265 Cr₹269 Cr₹321 Cr₹207 Cr₹231 Cr₹220 Cr₹326 Cr₹272 Cr₹335 Cr₹269 Cr₹283 Cr
₹1958 Cr₹2017 Cr₹1832 Cr₹1940 Cr₹1793 Cr₹1806 Cr₹1675 Cr₹1721 Cr₹1593 Cr₹1667 Cr₹1461 Cr₹1525 Cr₹1367 Cr₹1551 Cr₹1386 Cr₹1320 Cr₹1491 Cr₹1495 Cr₹1476 Cr₹1247 Cr₹1182 Cr₹1142 Cr₹1078 Cr₹1069 Cr₹1087 Cr₹995 Cr₹949 Cr₹1001 Cr₹820 Cr₹893 Cr₹870 Cr₹845 Cr₹684 Cr₹546 Cr₹546 Cr₹510 Cr₹425 Cr₹428 Cr₹369 Cr₹448 Cr₹300 Cr₹206 Cr₹184 Cr₹178 Cr₹175 Cr₹128 Cr₹133 Cr₹152 Cr₹213 Cr₹183 Cr₹185 Cr₹167 Cr₹175 Cr
₹1319 Cr₹1089 Cr₹978 Cr₹1033 Cr₹848 Cr₹972 Cr₹825 Cr₹822 Cr₹701 Cr₹810 Cr₹584 Cr₹565 Cr₹585 Cr₹553 Cr₹522 Cr₹701 Cr₹936 Cr₹1157 Cr₹1114 Cr₹837 Cr₹888 Cr₹740 Cr₹711 Cr₹755 Cr₹717 Cr₹521 Cr₹536 Cr₹538 Cr₹417 Cr₹457 Cr₹567 Cr₹602 Cr₹401 Cr₹331 Cr₹303 Cr₹275 Cr₹292 Cr₹258 Cr₹200 Cr₹291 Cr₹203 Cr₹127 Cr₹93 Cr₹105 Cr₹158 Cr₹92 Cr₹111 Cr₹81 Cr₹126 Cr₹102 Cr₹163 Cr₹112 Cr₹118 Cr
₹6 Cr₹6 Cr₹6 Cr₹8 Cr₹3 Cr₹1 Cr₹0₹1 Cr₹0₹2 Cr₹0₹1 Cr₹0₹0₹0₹0₹0₹8 L₹23 L₹21 L₹28 L₹21 L₹27 L₹16 L₹23 L₹44 L₹2 Cr₹4 Cr₹32 L₹10 L₹3 Cr₹24 L₹64 L₹59 L₹48 L₹91 L₹35 L₹62 L₹44 L₹2 Cr₹99 L₹55 L₹53 L₹55 L₹0₹2 Cr₹3 Cr₹83 L₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr
₹1180 Cr₹963 Cr₹780 Cr₹912 Cr₹733 Cr₹864 Cr₹726 Cr₹722 Cr₹604 Cr₹713 Cr₹489 Cr₹469 Cr₹492 Cr₹466 Cr₹435 Cr₹615 Cr₹852 Cr₹1076 Cr₹1034 Cr₹760 Cr₹814 Cr₹669 Cr₹642 Cr₹693 Cr₹661 Cr₹471 Cr₹487 Cr₹488 Cr₹373 Cr₹415 Cr₹522 Cr₹559 Cr₹359 Cr₹286 Cr₹274 Cr₹249 Cr₹268 Cr₹237 Cr₹179 Cr₹272 Cr₹188 Cr₹113 Cr₹80 Cr₹91 Cr₹146 Cr₹77 Cr₹95 Cr₹67 Cr₹111 Cr₹88 Cr₹149 Cr₹100 Cr₹106 Cr
₹902 Cr₹751 Cr₹583 Cr₹689 Cr₹545 Cr₹662 Cr₹589 Cr₹510 Cr₹430 Cr₹538 Cr₹358 Cr₹348 Cr₹356 Cr₹321 Cr₹306 Cr₹493 Cr₹702 Cr₹895 Cr₹902 Cr₹606 Cr₹557 Cr₹502 Cr₹471 Cr₹520 Cr₹492 Cr₹388 Cr₹359 Cr₹357 Cr₹272 Cr₹292 Cr₹389 Cr₹404 Cr₹268 Cr₹231 Cr₹217 Cr₹196 Cr₹215 Cr₹181 Cr₹140 Cr₹217 Cr₹175 Cr₹98 Cr₹72 Cr₹84 Cr₹129 Cr₹68 Cr₹85 Cr₹58 Cr₹107 Cr₹80 Cr₹135 Cr₹94 Cr₹93 Cr

Share Price Live Stats

Open (₹)9,244.00
Volume (₹)2.50 L
High (₹)9,269.00
Upper Circuit9,420.50
Low (₹)9,100.00
Lower Circuit8,872.50
Prev Close9,250.00
52W High (₹)9,467.00
Price9,100.00
52W Low (₹)5,636.50

Share Market Cap & Key Ratios Overview

M.Cap (₹)245426.00 Cr
Div. Yield (%)0.32
PE Ratio83.91
Debt to Equity0.00
Price to Book9.40
Book Value632.49
EPS (TTM)110.18
Face Value2.00
ROE (%)16.19

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LTP
1W Low
1W High
Market cap (₹)
1899-21 (-1.09%)
1895
1984.80
4,56,833Cr
9100-139 (-1.50%)
9087
9467
2,45,426Cr
4857-193 (-3.82%)
4823
5066
1,87,320Cr
1120-71 (-5.96%)
1120
1187
1,13,217Cr
1385-38.5 (-2.70%)
1375.50
1426.10
1,12,212Cr
1840-98.5 (-5.08%)
1811.70
1949
1,01,155Cr
2110-61.5 (-2.83%)
2100.60
2192
97,626Cr
2327.9-55 (-2.31%)
2317
2419.20
96,859Cr
1151-27 (-2.29%)
1151
1179.90
96,406Cr
1653.1+7.8 (0.47%)
1622.60
1717
93,614Cr

Key Highlights of Divi's Laboratories Ltd’s P&L

In 2026-03-31, Divi's Laboratories Ltd reported total revenue of ₹11067Cr, compared with ₹9714Cr in 2025-03-31, reflecting Divi's Laboratories Ltd turnover.

Depreciation was ₹463Cr and finance costs were ₹24Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹3388Cr in 2026-03-31 as compared to ₹2916Cr in 2025-03-31.

Net Profit (PAT) was ₹2568Cr in 2026-03-31 compared with ₹2191Cr in 2025-03-31.

Earnings per share (EPS) were ₹96.91 in 2026-03-31, compared with ₹82.68 in 2025-03-31.